D
David A. Cooper
Researcher at Pfizer
Publications - 965
Citations - 81765
David A. Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Viral load. The author has an hindex of 117, co-authored 903 publications receiving 69249 citations. Previous affiliations of David A. Cooper include Boston Children's Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid.
TL;DR: Differences in the positions and frequencies of wild-type and drug selected variants in specimens derived from the CSF and blood compartments were detected in a significant number of patients; this argues for the independent development of drug resistance in the CNS in some patients.
Journal ArticleDOI
Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
Jacob Hurst,Matthias Hoffmann,M Pace,M Pace,James P. Williams,John Thornhill,Elizabeth Hamlyn,J Meyerowitz,Chris Willberg,Kersten K. Koelsch,Nicola Robinson,Nicola Robinson,Helen Brown,Helen Brown,Martin Fisher,Sabine Kinloch,David A. Cooper,Mauro Schechter,Giuseppe Tambussi,Sarah Fidler,Abdel Babiker,Jonathan Weber,Anthony D. Kelleher,Rodney E. Phillips,Rodney E. Phillips,John Frater,John Frater +26 more
TL;DR: It is shown that immunological biomarkers can predict time to viral rebound after stopping ART by analysing data from a randomized study of primary HIV-1 infection incorporating a treatment interruption (TI) after 48 weeks of ART (the SPARTAC trial).
Posted ContentDOI
BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Ugur Sahin,Alexander Muik,Isabel Vogler,Evelyna Derhovanessian,Lena M. Kranz,Mathias Vormehr,Jasmin Quandt,Nicole Bidmon,Alexander Ulges,Alina Baum,Kristen E. Pascal,Daniel Maurus,Sebastian Brachtendorf,Verena L Loerks,Julian Sikorski,Peter Koch,Rolf Hilker,Dirk Becker,Ann-Kathrin Eller,Jan Gruetzner,Manuel Tonigold,Carsten Boesler,Corinna Rosenbaum,Ludwig Heesen,Marie-Cristine Kuehnle,Asaf Poran,Jesse Z. Dong,Ulrich Luxemburger,Alexandra Kemmer-Brueck,David J. Langer,Martin Bexon,Stefanie Bolte,Tania Palanche,Armin Schultz,Sybille Baumann,Azita J. Mahiny,Gábor Boros,Jonas Reinholz,Gabor T Szabo,Katalin Karikó,Pei Yong Shi,Camila R. Fontes-Garfias,John L. Perez,Mark Cutler,David A. Cooper,Christos A. Kyratsous,Philip R. Dormitzer,Kathrin U. Jansen,Oezlem Tuereci +48 more
TL;DR: Vaccination with BNT162b2 at well tolerated doses elicits a combined adaptive humoral and cellular immune response, which together may contribute to protection against COVID-19.
Journal ArticleDOI
Low Bone Mineral Density, Renal Dysfunction, and Fracture Risk in HIV Infection: A Cross-Sectional Study
Alexandra Calmy,Alexandra Calmy,Christoph A Fux,Richard Norris,Nathalie Vallier,Cécile Delhumeau,Katherine Samaras,Karl Hesse,Bernard Hirschel,David A. Cooper,David A. Cooper,Andrew Carr +11 more
TL;DR: Measurement of BMD and estimation of fracture risk may be warranted in treated HIV-infected adults, and tenofovir recipients showed evidence of increased bone turnover.
Journal ArticleDOI
Subtypes of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma.
MJ Boyle,William A. Sewell,TB Sculley,A Apolloni,Jennifer Turner,CE Swanson,Ronald Penny,David A. Cooper +7 more
TL;DR: The hypothesis that Epstein-Barr virus is an important cofactor in NHL in HIV-infected persons and the finding that B-type EBV is present in 25% of HIV-associated NHL suggests that this EBV subtype may be an important human pathogen with a wider geographic distribution than originally thought.